Chinese pharmaceutical and health-products conglomerate (Haiwang brand) spanning generics, nutraceuticals and pharmacy retail.
Chinese pharmaceutical and health-products conglomerate (Haiwang brand) spanning generics, nutraceuticals and pharmacy retail.
Sells prescription drugs to hospitals, largely through Livzon Pharmaceutical Group, a separately listed drugmaker it controls, and sells nutraceuticals and health products to consumers through pharmacies and retail channels under its Haiwang brand. Livzon's own shares trade separately in Shenzhen and Hong Kong.
Moat: narrow (brand, distribution). Established Haiwang consumer brand plus a diversified generics/retail distribution network.
Headquarters: Shenzhen, China · Employees: 13,575
Size Joincare Pharmaceutical Group Industry (600380.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.85B, the 845th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥10.53 on 18 Nov 2026.
Performance Over six months the shares gained 0.4%, against -9.7% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue fell 11.8% over the last twelve months (peer median +14.8%); the operating margin is 17.6% (peer median 12.0%).
Valuation It trades at 15.5× forward earnings against a peer median of 27.1× (4th cheapest of 18).
Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is +2%, so the hurdle is -15 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.2 points above its cost of capital (5.0% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥13.4B | CN¥15.1B | CN¥15.5B | CN¥16.5B | CN¥17.0B |
| Revenue growth | — | -3% | -6% | -3% | — |
| Gross profit | CN¥8.38B | CN¥9.12B | CN¥9.40B | CN¥9.65B | CN¥10.4B |
| EBITDA | n/a | CN¥3.89B | CN¥4.17B | CN¥4.28B | CN¥4.08B |
| Net income | CN¥1.13B | CN¥1.34B | CN¥1.39B | CN¥1.44B | CN¥1.50B |
| Free cash flow | CN¥3.04B | CN¥3.16B | CN¥2.68B | CN¥2.95B | CN¥2.97B |
| Capital expenditure | CN¥709M | CN¥767M | CN¥979M | CN¥1.13B | CN¥1.15B |
| Total debt | CN¥5.80B | CN¥5.50B | CN¥6.68B | CN¥7.40B | CN¥7.08B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Joincare Pharmaceutical Group Industry 600380.SS | $2.85B | 0% | -12% | 18% | 15.5× | -13.1% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% |
| By-health 300146.SZ | $2.56B | -1% | +10% | 11% | 24.7× | 4.8% |
| Yunnan Baiyao 000538.SZ | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% |
| Cspc Pharma 1093.HK | $12.0B | +10% | +25% | 28% | 9.1× | -10.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600380.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.9% | -1.4% | 2nd highest of 21 |
| 6-month return | +0.4% | -9.7% | 6th highest of 21 |
| Distance from 52-week high | -18.1% | -38.0% | 6th highest of 21 |
| Revenue growth (TTM) | -11.8% | +14.8% | 5th lowest of 20 |
| Operating margin | 17.6% | 12.0% | 9th highest of 20 |
| Forward P/E | 15.5× | 27.1× | 4th cheapest of 18 |
| Growth the price implies (Req g, 7 yrs) | -13.1% | 6.1% | least demanding of 16 |
| Growth delivered (Del g) | +2.4% | +6.5% | 2nd lowest of 16 |
| Hurdle (Req g minus delivered) | -15.5 pp | -1.3 pp | 4th least demanding of 16 |
| ROIC minus cost of capital | +4.2 pp | +1.2 pp | 7th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Joincare Pharmaceutical Group Industry 600380.SS | China | $2.85B | 0% | -12% | 18% | 15.5× | -13.1% | +2.4% |
| Neuland Laboratories NEULANDLAB.NS | India | $2.95B | +28% | +50% | 26% | 63.4× | n/a | n/a |
| China Medical System 0867.HK | Hong Kong | $2.95B | -15% | +15% | 20% | 9.8× | 1.1% | +2.7% |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $2.99B | -1% | -11% | 24% | 20.1× | -3.3% | +7.0% |
| Vericel VCEL | United States | $2.99B | +66% | +25% | 8% | 68.3× | 46.5% | +17.3% |
| Betta Pharmaceuticals 300558.SZ | China | $2.70B | -15% | +16% | 11% | 38.0× | 23.2% | +14.0% |
| Hybio Pharmaceutical 300199.SZ | China | $2.68B | -8% | +70% | 31% | 44.7× | 37.4% | +6.1% |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.05B | -39% | +33% | 12% | 21.3× | 14.1% | +61.4% |
| BioArctic BIOA-B.ST | Sweden | $2.66B | -9% | -46% | 22% | 52.9× | 25.5% | +100.1% |
| ACADIA Pharmaceuticals ACAD | United States | $3.08B | -15% | +15% | 10% | 17.8× | 9.2% | +19.4% |
| Kangmei Pharmaceutical 600518.SS | China | $2.61B | -21% | -6% | -7% | n/a | n/a | n/a |
| Legend Biotech Corp. Sponsored ADR LEGN | United States | $3.12B | -42% | +50% | 3% | 34.2× | n/a | n/a |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.13B | -25% | +136% | 29% | 36.1× | 17.7% | +98.4% |
| IDEAYA Biosciences IDYA | United States | $2.56B | -11% | -83% | -1,267% | n/a | n/a | n/a |
| Tasly Pharmaceutical 600535.SS | China | $3.19B | -2% | -4% | 19% | 16.7× | -7.5% | -9.6% |
| China National Medicines 600511.SS | China | $3.26B | +3% | +3% | 4% | 10.5× | -10.0% | +5.4% |
| Yili Chuanning Biotechnology 301301.SZ | China | $2.49B | -24% | -14% | 16% | 27.6× | 3.4% | +4.8% |
| Almirall ALM.MC | Spain | $2.46B | -13% | +24% | 8% | 27.1× | 6.1% | +6.5% |
| Viking Therapeutics VKTX | United States | $3.34B | -9% | n/a | n/a | n/a | n/a | n/a |
| Apeloa Pharmaceutical 000739.SZ | China | $3.37B | +17% | -16% | 10% | 22.9× | 4.7% | +4.5% |
| Prestige Consumer Healthcare PBH | United States | $2.40B | +7% | +5% | 25% | 10.6× | 2.3% | +2.9% |